导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.50% | 1873/4773 |
| 近一周 | -3.13% | 3728/5462 |
| 近一月 | -9.88% | 4908/5421 |
| 近一季 | -18.50% | 4712/5209 |
| 近半年 | -1.37% | 1568/4920 |
| 近一年 | 5.78% | 1548/4366 |
| 近两年 | 105.97% | 540/2954 |
| 近三年 | 63.34% | 397/2253 |
| 成立以来 | 95.09% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.86% 1994/4961 |
34.72% 951/5312 |
- - |
- - |
| 2025 | 48.47% 523/4813 |
-1.39% 2653/3635 |
3.18% 1125/4076 |
47.54% 452/4524 |
-1.10% 2823/4813 |
| 2024 | 13.83% 1102/3463 |
-3.54% 1519/2808 |
-6.14% 1863/3014 |
27.55% 217/3129 |
-1.44% 1701/3463 |
| 2023 | -16.70% 1694/2656 |
2.26% 1387/2280 |
-6.71% 1691/2385 |
-8.20% 1677/2515 |
-4.88% 1199/2655 |
| 2022 | -26.89% 1440/2207 |
-18.70% 1380/1919 |
6.14% 764/2016 |
-17.37% 1586/2113 |
2.54% 904/2208 |
| 2021 | 15.73% 295/1822 |
-6.10% 977/1255 |
26.47% 71/1330 |
-5.34% 798/1466 |
2.96% 490/1822 |
| 2020 | - - |
- - |
- - |
6.58% 826/1164 |
15.33% 219/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 东财创业板C VS. 长安沪深300非周期A(740101) |